1. terminally ill patients due to underlying cardiac, cancer or severe debilitating neurological disease including coma; 2. hospitalization expected to be \< 96 hours due to medical improvement; 3. interstitial lung disease; 4. correction of qtc values obtained by 12 lead ekg using fredericia's formula (qtcf) \> 450 ms; 5. history of hypotension (mean arterial blood pressure \< 65 mmhg), unrelated to covid-19 infection; 6. alanine aminotransferase (alt) or aspartate aminotransferase (ast) \> 3 times upper limit of normal; 7. participating concurrently on another clinical trial for the experimental treatment of covid-19; 8. active chemotherapy use; 9. pregnant and/or lactating women.

1. terminally ill patients due to underlying cardiac, cancer or severe debilitating neurological disease including coma; 2. hospitalization expected to be \< 96 hours due to medical improvement; 3. interstitial lung disease; 4. correction of qtc values obtained by 12 lead ekg using fredericia's formula (qtcf) \> 450 ms; 5. history of hypotension (mean arterial blood pressure \< 65 mmhg), unrelated to covid-19 infection; 6. alanine aminotransferase (alt) or aspartate aminotransferase (ast) \> 3 times upper limit of normal; 7. participating concurrently on another clinical trial for the experimental treatment of covid-19; 8. active chemotherapy use; 9. pregnant and/or lactating women.

terminally ill patients due to underlying cardiac, cancer or severe debilitating neurological disease including coma; hospitalization expected to be < 96 hours due to medical improvement; interstitial lung disease; correction of qtc values obtained by 12 lead ekg using fredericia's formula (qtcf) > 450 ms; history of hypotension (mean arterial blood pressure < 65 mmhg), unrelated to covid-19 infection; alanine aminotransferase (alt) or aspartate aminotransferase (ast) > 3 times upper limit of normal; participating concurrently on another clinical trial for the experimental treatment of covid-19; active chemotherapy use; pregnant and/or lactating women.

terminally ill patients due to underlying cardiac, cancer or severe debilitating neurological disease including coma; hospitalization expected to be < 96 hours due to medical improvement; interstitial lung disease; correction of qtc values obtained by 12 lead ekg using fredericia's formula (qtcf) > 450 ms; history of hypotension (mean arterial blood pressure < 65 mmhg), unrelated to covid-19 infection; alanine aminotransferase (alt) or aspartate aminotransferase (ast) > 3 times upper limit of normal; participating concurrently on another clinical trial for the experimental treatment of covid-19; active chemotherapy use; pregnant and/or lactating women.

1. terminally ill patients due to underlying cardiac, cancer or severe debilitating neurological disease including coma; 2. hospitalization expected to be < 96 hours due to medical improvement; 3. interstitial lung disease; 4. correction of qtc values obtained by 12 lead ekg using fredericia's formula (qtcf) > 450 ms; 5. history of hypotension (mean arterial blood pressure < 65 mmhg), unrelated to covid-19 infection; 6. alanine aminotransferase (alt) or aspartate aminotransferase (ast) > 3 times upper limit of normal; 7. participating concurrently on another clinical trial for the experimental treatment of covid-19; 8. active chemotherapy use; 9. pregnant and/or lactating women.

1. terminally ill patients due to underlying cardiac, cancer or severe debilitating neurological disease including coma; 2. hospitalization expected to be < 96 hours due to medical improvement; 3. interstitial lung disease; 4. correction of qtc values obtained by 12 lead ekg using fredericia's formula (qtcf) > 450 ms; 5. history of hypotension (mean arterial blood pressure < 65 mmhg), unrelated to covid-19 infection; 6. alanine aminotransferase (alt) or aspartate aminotransferase (ast) > 3 times upper limit of normal; 7. participating concurrently on another clinical trial for the experimental treatment of covid-19; 8. active chemotherapy use; 9. pregnant and/or lactating women.